We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Technique Catalogs Lymphoma-Linked Genetic Variations

By LabMedica International staff writers
Posted on 17 Jan 2013
A novel approach has been devised to sort out random mutations in genes associated with lymphoma, and the proteins produced by the genes could be tested to see how they performed. More...


Antigen receptor signaling to nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB), is essential for normal lymphocyte activation, but is dysregulated in several types of lymphoma.

Scientists at Johns Hopkins School of Medicine (Baltimore, MD, USA) made copies of the caspase recruitment domain family, member 11 (CARD11) gene in a way that made random mutations likely. The CARD11 protein plays a key role in signaling the presence of infection, which leads infection-fighting white blood cells to grow and divide.

The investigators then used the faulty copies to make mutant proteins, and tested the ability of those proteins to trigger the signaling reaction that is CARD11's specialty. This allowed them to find to which mutations increased the protein's activity and by how much and this information could then be compared to emerging data about CARD11 mutations found in human lymphomas. They noted that CARD11 is part of the NF- κB signaling pathway, a target of some cancer therapies
.
Joel Pomerantz, PhD, an associate professor in the Johns Hopkins School of Medicine's Institute for Cell Engineering, and senior author of the study said "Our goal was to correlate various mutations with potential to promote lymphoma. We imagine eventually being able to correlate response to a particular therapy with a particular mutation." The cancers called lymphomas, affect about 75,000 patients in the United States of America each year. The study was published in the January 2013 issue of the journal Molecular and Cellular Biology.

Related Links:

Johns Hopkins School of Medicine




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.